| “Bioengineering and Medtech against Cancer” Free online short course November 24 and 25, 2020 |
| Cancer is one of the main challenges in medicine and advances in recent years show that much of the solution involves an innovation model based on collaboration among scientists, engineers and doctors. With this in mind, the two-day online short course “Bioengineering and Medtech against Cancer” aims to educate the next generation of healthcare professionals and researchers, boost international projection of EU projects and create new collaborative networks with key experts from each area. This short course will include lectures, panel discussions and expert meetings analyzing and discussing the main hot topics in technology that will revolutionize healthcare and assistance for cancer patients. |
| Pitching session A pitch session will allow 12 startups, potential entrepreneurs (at the proof of concept stage) and project holders working on cancer to pitch their work to investors and experts. Take this unique opportunity to get constructive feedback! |
| Partnering Session Plus, anyone who submits an abstract will have the opportunity to meet and pitch their project in private meetings with international VCs and corporates. Confirmed VCs include Invivo Capital, Aurora-TT, Sanofi Ventures, Kurma Partners, Fund+, Caixa Capital Risc and Ysios Capital. More to come! |
| Deadline: October 2, 2020 |
| Program |
| November 2409:00 am Opening ceremony09:15 am Liquid biopsies – Towards an early diagnosis and real-time monitoring of cancer10:30 am Tumor-on-chip – a 3D tool for precision oncology2:00 pm CAR-T cells: engineering patients’ immune cells for cancer treatment3:10 am Mechanics of cancer growth and migration4:15 pm Open round table for the general public November 259:00 am Tumor-targeted drug-delivery systems 10:15 am Making it happen 2:00 pm Pitches from startups and R&D projects3:30 pm Partnering session5:15 pm Closing |
| This short course is part of the ToHealth program, an EIT Health activity. The event is organized by Medicen Paris and the Institute for Bioengineering of Catalonia (IBEC), with the collaboration of Biocat, “la Caixa” Foundation and Meditecnologia, under the framework of B·Debate. |
